Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated May 18, 2011, announces the provision of unaudited restated and pro forma consolidated income statement data following the completion of the merger with Alcon, Inc. The new divisional reporting structure is effective from the second quarter of 2011. The filing clarifies that while segmental data has been amended to reflect the new structure, the Group's total consolidated income statement data previously released on April 19, 2011, remains unchanged.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the current period within this text. It references historical data from 2010, noting that the Group's continuing operations achieved net sales of USD 50.6 billion and invested approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) in R&D activities. The document focuses on the methodology for restating data rather than presenting new financial totals.
Material Changes and Reporting Structure
- Divisional Realignment: The Alcon Division now includes CIBA Vision and certain ophthalmology products from the Pharmaceuticals Division.
- Sandoz Division: Falcon, the US generics business of Alcon, Inc., has been transferred to the Sandoz Division.
- Corporate Costs: Certain residual operational costs for the Consumer Health Division headquarters are transferred to Corporate.
- Pro Forma Adjustments: Supplementary pro forma data for 2010 reflects the consolidation of Alcon, Inc. as if it occurred on January 1, 2010, including 100% consolidation for the full year. This data adjusts for divestments required by regulators and exceptional acquisition costs.
- Scope Limitation: No pro forma data is provided below the operating income level.
Outlook, Risks, and Management Commentary
Management indicates that an investor call was held on May 18, 2011, to discuss the restated and pro forma data. The filing contains extensive forward-looking statements regarding potential synergies, strategic benefits, and future sales resulting from the merger. Management explicitly states there can be no guarantee that Novartis will realize these synergies or achieve particular financial results.
Key risks and uncertainties identified include:
- Unexpected regulatory actions, delays, or government investigations.
- Unexpected clinical trial results or issues with intellectual property protection.
- Disruptions from the merger and integration with Alcon affecting business relationships and employee retention.
- Product manufacturing issues and legal proceedings, including product liability and sales practice litigation.
- Global economic conditions, exchange rate fluctuations, and pricing pressures.
Investor Verification Checklist
- Verify the specific numerical values for the restated and pro forma consolidated income statements on the Novartis website, as this filing text does not contain the detailed tables.
- Confirm the impact of the Alcon merger on the Pharmaceuticals and Sandoz divisions' specific operating income.
- Review the full Form 20-F for detailed risk factors and historical financial data referenced in the disclaimer.
- Monitor the integration progress of Alcon, Inc. and the realization of projected synergies against the forward-looking statements provided.